We and others demonstrated in melanoma that ASO strategy is feasible in vivo by targeting SAMMSON mRNA and the lncRNA TYRP1 (Leucci et al,2016; Gilot et al,2017). The gene discussed is SAMMSON; the disease is melanoma.